AR047098A1 - Derivados de arilanilina como agonistas del receptor adrenergico beta2 - Google Patents
Derivados de arilanilina como agonistas del receptor adrenergico beta2Info
- Publication number
- AR047098A1 AR047098A1 ARP050100092A ARP050100092A AR047098A1 AR 047098 A1 AR047098 A1 AR 047098A1 AR P050100092 A ARP050100092 A AR P050100092A AR P050100092 A ARP050100092 A AR P050100092A AR 047098 A1 AR047098 A1 AR 047098A1
- Authority
- AR
- Argentina
- Prior art keywords
- atom
- alkyl
- attached
- 6alkylene
- nhc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Abstract
Composiciones farmacéuticas que comprenden dichos compuestos, métodos para utilizar dichos compuestos para tratar enfermedades asociadas con la actividad del receptor adrenérgico b2, y procesos e intermediarios utiles para preparar dichos compuestos. Reivindicacion 1: Un compuesto caracterizado porque es de la formula (1) donde: cada uno de R1, R2, R3, y R4 se selecciona en forma independiente entre H, hidroxi, amino, halo, -CH2OH y -NHCHO, o R1 y R2 juntos se seleccionan entre - NHC(=O)CH=CH, -CH=CHC(=O)NH-, -NHC(=O)S-; y -SC(=O)NH-; uno de R5 y R6 es -[X-C1-6alquilenil]n-NR10R11 o C1-6alquilenil-NR12R13, y el otro de R5 y R6 se selecciona entre H, hidroxi, C1-4alcoxi, y C1-4 alquilo, donde C1-4 alquilo está opcionalmente sustituido con halo, donde cada X se selecciona en forma independiente entre -O-, -NH-, -S-, -NHSO2-, -SO2NH-, -NHC(=O)-, y -C(=O)NH-; cada uno de R10, R11, R12 y R13 es en forma independiente H o C1-4 alquilo; o R10 y R11, junto con el átomo de N al cual están unidos, o R10, junto con el átomo de N al cual está unido y un átomo de C del C1-6alquilenilo adyacente, o R12 y R13, junto con el átomo de N al cual están unidos, o R12, junto con el átomo de N al cual está unido y un átomo de C del C1-6 alquilenilo adyacente, forman un anillo heterocíclico o heteroarilo con entre 5 y 7 átomos en el anillo, y que contiene opcionalmente un heteroátomo adicional seleccionado entre O, N, y S, donde el N está opcionalmente sustituido con -S(O)2-C1- 4alquilo; y n es 1, 2 o 3; y cada uno de R7, R8, y R9 es en forma independiente H o C1-6 alquilo; o una sal o solvato o estereoisomero aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53578404P | 2004-01-12 | 2004-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047098A1 true AR047098A1 (es) | 2006-01-04 |
Family
ID=34806964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100092A AR047098A1 (es) | 2004-01-12 | 2005-01-11 | Derivados de arilanilina como agonistas del receptor adrenergico beta2 |
Country Status (20)
Country | Link |
---|---|
US (3) | US7622467B2 (es) |
EP (1) | EP1706371B1 (es) |
JP (1) | JP5041814B2 (es) |
KR (1) | KR20070000466A (es) |
CN (1) | CN1910137B (es) |
AR (1) | AR047098A1 (es) |
AT (1) | ATE504559T1 (es) |
AU (1) | AU2005206510A1 (es) |
BR (1) | BRPI0506823A (es) |
CA (1) | CA2551821A1 (es) |
DE (1) | DE602005027307D1 (es) |
ES (1) | ES2364450T3 (es) |
IL (1) | IL176549A0 (es) |
MA (1) | MA28304A1 (es) |
NO (1) | NO20063620L (es) |
NZ (1) | NZ548196A (es) |
RU (1) | RU2370490C2 (es) |
TW (1) | TW200531692A (es) |
WO (1) | WO2005070872A1 (es) |
ZA (1) | ZA200605720B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200134B1 (en) | 1998-01-20 | 2001-03-13 | Kerr Corporation | Apparatus and method for curing materials with radiation |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
US7182597B2 (en) | 2002-08-08 | 2007-02-27 | Kerr Corporation | Curing light instrument |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
CA2569395A1 (en) * | 2004-06-03 | 2005-12-22 | Theravance, Inc. | Diamine .beta.2 adrenergic receptor agonists |
JP2008507532A (ja) * | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
US7566785B2 (en) * | 2004-09-10 | 2009-07-28 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
NZ556335A (en) * | 2005-01-11 | 2009-07-31 | Glaxo Group Ltd | Cinnamate salts of a beta-2 adrenergic agonist |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
US8113830B2 (en) | 2005-05-27 | 2012-02-14 | Kerr Corporation | Curing light instrument |
RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
DK2013211T3 (da) | 2006-04-21 | 2012-07-02 | Novartis Ag | Purinderivater til anvendelse som adenosin-A2A-receptoragonister |
TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
ES2306595B1 (es) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
AU2009260899B2 (en) | 2008-06-18 | 2012-02-23 | Astrazeneca Ab | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EA019441B1 (ru) | 2008-12-30 | 2014-03-31 | Палмаджен Терепьютикс (Инфлеммейшн) Лимитед | Сульфонамиды, предназначенные для лечения респираторных нарушений |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
EP2678338B1 (en) | 2011-02-25 | 2015-09-09 | Novartis AG | Pyrazolo[1,5-a]pyridines as trk inhibitors |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1250450B (de) | 1962-03-31 | 1967-09-21 | Deutsche Gold- und Silber-Scheideanstalt vormals Roessler, Frankfurt/M | Verfahren zur Herstellung von Aminoalkoholen sowie deren Säureadditionssalzen und quartären Ammoniumverbindungen |
AT310146B (de) | 1971-04-26 | 1973-09-25 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen |
CH545764A (es) | 1971-07-27 | 1974-02-15 | ||
BE794414A (fr) | 1972-01-25 | 1973-07-23 | Sandoz Sa | Nouveaux amino-alcools, leur preparation et leur application comme medicament |
FR2266497B1 (es) | 1974-04-03 | 1977-11-04 | Roussel Uclaf | |
JPS5913510B2 (ja) | 1975-12-26 | 1984-03-30 | オオツカセイヤク カブシキガイシヤ | カルボスチリルユウドウタイノセイゾウホウ |
JPS5283619A (en) | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Alpha-substituted aminomethyl benzyl alcohol derivative |
JPS609713B2 (ja) | 1976-10-08 | 1985-03-12 | 大塚製薬株式会社 | カルボスチリル誘導体 |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
GB8507942D0 (en) | 1985-03-27 | 1985-05-01 | Beecham Group Plc | Compounds |
DK9987A (da) | 1986-01-11 | 1987-07-12 | Beecham Group Plc | Ethanolaminderivater |
US5223614A (en) * | 1987-12-19 | 1993-06-29 | Boehringer Ingelheim Gmbh | New quaternary ammonium compounds, their preparation and use |
US4894219A (en) | 1988-03-29 | 1990-01-16 | University Of Florida | Beta-agonist carbostyril derivatives, assay method and pharmacological composition |
US5434304A (en) * | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
US5808080A (en) * | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
GB9713819D0 (en) * | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
US6713651B1 (en) * | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
WO2001083462A1 (de) * | 2000-04-27 | 2001-11-08 | Boehringer Ingelheim Pharma Kg | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
ES2265447T3 (es) * | 2000-11-10 | 2007-02-16 | Eli Lilly And Company | Agonistas de receptor beta-3 de oxindol-3-sustituido. |
GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) * | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ES2296923T3 (es) * | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
EP2042168B1 (en) | 2001-09-14 | 2013-10-23 | Glaxo Group Limited | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
US6747043B2 (en) * | 2002-05-28 | 2004-06-08 | Theravance, Inc. | Alkoxy aryl β2 adrenergic receptor agonists |
EP1546086A2 (en) | 2002-06-27 | 2005-06-29 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
EP1622875B1 (en) * | 2003-05-08 | 2009-12-02 | Theravance, Inc. | Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist |
US7556785B2 (en) * | 2003-05-12 | 2009-07-07 | United Phosphorus, Ltd. | Apparatus and method for rapid and continuous generation of phosphine gas |
TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
CA2569395A1 (en) * | 2004-06-03 | 2005-12-22 | Theravance, Inc. | Diamine .beta.2 adrenergic receptor agonists |
JP2008507532A (ja) * | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
US7566785B2 (en) * | 2004-09-10 | 2009-07-28 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
-
2004
- 2004-12-30 TW TW093141433A patent/TW200531692A/zh unknown
-
2005
- 2005-01-11 CA CA002551821A patent/CA2551821A1/en not_active Abandoned
- 2005-01-11 BR BRPI0506823-1A patent/BRPI0506823A/pt not_active IP Right Cessation
- 2005-01-11 WO PCT/US2005/000810 patent/WO2005070872A1/en active Application Filing
- 2005-01-11 EP EP05711348A patent/EP1706371B1/en active Active
- 2005-01-11 US US11/033,198 patent/US7622467B2/en active Active
- 2005-01-11 ES ES05711348T patent/ES2364450T3/es active Active
- 2005-01-11 AR ARP050100092A patent/AR047098A1/es unknown
- 2005-01-11 KR KR1020067015602A patent/KR20070000466A/ko not_active Application Discontinuation
- 2005-01-11 AU AU2005206510A patent/AU2005206510A1/en not_active Abandoned
- 2005-01-11 RU RU2006129312/04A patent/RU2370490C2/ru not_active IP Right Cessation
- 2005-01-11 DE DE602005027307T patent/DE602005027307D1/de active Active
- 2005-01-11 NZ NZ548196A patent/NZ548196A/xx unknown
- 2005-01-11 CN CN2005800022796A patent/CN1910137B/zh not_active Expired - Fee Related
- 2005-01-11 AT AT05711348T patent/ATE504559T1/de not_active IP Right Cessation
- 2005-01-11 JP JP2006549523A patent/JP5041814B2/ja not_active Expired - Fee Related
-
2006
- 2006-06-26 IL IL176549A patent/IL176549A0/en unknown
- 2006-07-11 ZA ZA200605720A patent/ZA200605720B/xx unknown
- 2006-07-24 MA MA29204A patent/MA28304A1/fr unknown
- 2006-08-09 NO NO20063620A patent/NO20063620L/no not_active Application Discontinuation
-
2009
- 2009-10-06 US US12/574,066 patent/US7994165B2/en not_active Expired - Fee Related
-
2011
- 2011-06-28 US US13/170,386 patent/US20120071654A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2006129312A (ru) | 2008-02-20 |
CA2551821A1 (en) | 2005-08-04 |
CN1910137A (zh) | 2007-02-07 |
NZ548196A (en) | 2009-08-28 |
AU2005206510A1 (en) | 2005-08-04 |
MA28304A1 (fr) | 2006-11-01 |
EP1706371B1 (en) | 2011-04-06 |
WO2005070872A1 (en) | 2005-08-04 |
BRPI0506823A (pt) | 2007-05-29 |
US20120071654A1 (en) | 2012-03-22 |
JP2007518738A (ja) | 2007-07-12 |
EP1706371A1 (en) | 2006-10-04 |
ES2364450T3 (es) | 2011-09-02 |
DE602005027307D1 (de) | 2011-05-19 |
US20050159448A1 (en) | 2005-07-21 |
JP5041814B2 (ja) | 2012-10-03 |
US20100087410A1 (en) | 2010-04-08 |
US7622467B2 (en) | 2009-11-24 |
KR20070000466A (ko) | 2007-01-02 |
RU2370490C2 (ru) | 2009-10-20 |
US7994165B2 (en) | 2011-08-09 |
NO20063620L (no) | 2006-10-06 |
ZA200605720B (en) | 2008-09-25 |
TW200531692A (en) | 2005-10-01 |
CN1910137B (zh) | 2010-05-26 |
IL176549A0 (en) | 2006-10-31 |
ATE504559T1 (de) | 2011-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
MX362920B (es) | Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina. | |
ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
CL2009000127A1 (es) | Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1. | |
AR037983A1 (es) | Derivados de pirido [2,1-a] isoquinolina | |
WO2009082268A3 (ru) | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
PE20170323A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
AR074855A1 (es) | Derivados aminoester de alcaloides y composicion medicinal de los mismos utilizadas en el tratamiento de enfermedades mediadas por el antagonismo de los receptores muscarinicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |